Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Net Income (2017 - 2025)

Aclaris Therapeutics has reported Net Income over the past 9 years, most recently at -$21.1 million for Q4 2025.

  • Quarterly results put Net Income at -$21.1 million for Q4 2025, up 78.37% from a year ago — trailing twelve months through Dec 2025 was -$68.7 million (up 48.69% YoY), and the annual figure for FY2025 was -$68.7 million, up 47.95%.
  • Net Income for Q4 2025 was -$21.1 million at Aclaris Therapeutics, down from -$15.3 million in the prior quarter.
  • Over the last five years, Net Income for ACRS hit a ceiling of -$1.9 million in Q4 2023 and a floor of -$97.6 million in Q4 2024.
  • Median Net Income over the past 5 years was -$20.6 million (2021), compared with a mean of -$23.8 million.
  • Biggest five-year swings in Net Income: plummeted 66588.89% in 2021 and later skyrocketed 93.61% in 2023.
  • Aclaris Therapeutics' Net Income stood at -$22.9 million in 2021, then dropped by 27.02% to -$29.1 million in 2022, then skyrocketed by 93.61% to -$1.9 million in 2023, then plummeted by 5151.45% to -$97.6 million in 2024, then soared by 78.37% to -$21.1 million in 2025.
  • The last three reported values for Net Income were -$21.1 million (Q4 2025), -$15.3 million (Q3 2025), and -$16.4 million (Q2 2025) per Business Quant data.